A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium

Summary

Approximately 36 HIV-negative women, aged \>18 and \< 50, will be enrolled in this study. Each volunteer will have a 2:1 chance of receiving dapivirine gel versus placebo. The volunteers will receive investigational product for a total of 42 days.

Timeline

Start

2005-12

Primary completion

—

Completion

—

Drugs

Indications